



## **EOS imaging Reports First quarter 2013 Revenues of €1.9m**

**Paris, April 23, 2013** – EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced its revenue results for the first quarter ended March 31, 2013.

€m	Q1 2013	Q1 2012
Sales of equipment	<b>1.60</b>	0.41
% of total revenues	84.2%	73.3%
Sales of services	<b>0.30</b>	0.15
% of total revenues	15.8%	26.7%
<b>Total revenues</b>	<b>1.90</b>	<b>0.56</b>

### **Record sales in first quarter 2013**

EOS imaging reported record first quarter 2013 revenues of €1.9 million (Q1 2012: €0.56 million), driven by the sale of four EOS® systems, up from one system in the first quarter 2012, and by the maintenance services.

Sales of equipment increased by a factor of four to €1.6 million (Q1 2012: €0.41 million). The average sales price per EOS system in the first quarter 2013 was €400,000.

Sales of services doubled to €0.3 million compared to first quarter 2012, mostly driven by an increase in the number of installed systems under maintenance contracts.

### **First quarter 2013 driven by sales in North America**

€m	Q1 2013	Q1 2012
Europe	<b>0.60</b>	0.52
North America	<b>1.30</b>	0.04
Rest of world	<b>0.00</b>	0.00
<b>Total revenues</b>	<b>1.90</b>	<b>0.56</b>

69% of first quarter 2013 revenues (€1.30 million) came from North America, where the company sold three EOS systems. In Europe, revenues were €0.60 million, which included the sale of one system.

Marie Meynadier, CEO of EOS imaging, said: "We posted sharp growth in revenues during the first quarter, which was boosted by some second quarter orders being initiated. This improvement compared to the prior year reflects the first benefits from our investments to expand our North American sales presence in 2012."

**About EOS imaging:**

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). With an installed base of more than 60 sites and more than 350,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 63 people, including an R&D team of 23 engineers, and recorded consolidated revenue of €9.42 million in 2012. The Group's head office is based in Paris, with 3 international subsidiaries in Cambridge (Massachusetts), Montreal and Germany. For further information, please go to: [www.eos-imaging.com](http://www.eos-imaging.com).

**EOS imaging is listed on Compartment C of the NYSE Euronext Paris****ISIN: FR0011191766 – Ticker: EOSI****Next update: half year 2013 revenues: July 17, 2013 after market close****EOSI**  
LISTED  
NYSE  
EURONEXT**Contacts:****Anne Renevot****CFO**

Tel.: +33 (0)1 55 25 61 24

[investors@eos-imaging.com](mailto:investors@eos-imaging.com)**NewCap.**

Financial communication and investor relations

Sophie Boulila / Pierre Laurent

Tel.: +33 (0)1 44 71 94 91

[eosimaging@newcap.fr](mailto:eosimaging@newcap.fr)**The Ruth Group (US)**

Press Relations - Lisa Cook

Ph: 646-536-7012

[lcook@theruthgroup.com](mailto:lcook@theruthgroup.com)**ALIZE RP (Europe)**

Press Relations

Caroline Carmagnol

Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59

[caroline@alizerp.com](mailto:caroline@alizerp.com)